CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) — Reviva Prescribed drugs Holdings, Inc. (NASDAQ: RVPH) (Reviva or the Firm), a late-stage pharmaceutical firm growing therapies that search to deal with unmet medical wants within the areas of central nervous system (CNS), inflammatory and cardiometabolic ailments, right this moment introduced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will take part in a fireplace chat on the 2024 Maxim Healthcare Digital Summit, going down nearly October 15-17, 2024.
2024 Maxim Healthcare Digital Summit
Format: Hearth chat
Date: Tuesday, October 15, 2024
Time: 3:30 p.m. ET
Location: Digital
Registration Hyperlink: Click on Right here
About Reviva
Reviva is a late-stage biopharmaceutical firm that discovers, develops, and seeks to commercialize next-generation therapeutics for ailments representing unmet medical wants and burdens to society, sufferers, and their households. Reviva’s present pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic ailments. Reviva’s pipeline presently consists of two drug candidates, brilaroxazine (RP5063) and RP1208. Each are new chemical entities found in-house. Reviva has been granted composition of matter patents for each brilaroxazine and RP1208 in the US, Europe, and a number of other different international locations.
Company Contact:
Reviva Prescribed drugs Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
Supply: Reviva Prescribed drugs